All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes
Bookmark this article
The MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, What are the highlights of the ESH 8th Translational Research Conference: Myelodysplastic Syndromes?
Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes
De Witte begins by discussing new molecular MDS-specific mutations and how they can impact diagnosis and prognosis. De Witte goes on to define the pre-stages of MDS and myeloproliferative neoplasms (MPN), in particular clonal hematopoiesis of indeterminate potential (CHIP), and clonal cytopenia of undetermined significance (CCUS).
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox